share_log

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  2024/09/19 18:10

Moomoo AI 已提取核心信息

Addex Therapeutics announced a significant turnaround in its financial performance for H1 2024, posting a net profit of CHF 9.8 million compared to a net loss of CHF 5.1 million in H1 2023. This CHF 14.9 million improvement primarily stems from the April 2, 2024 partial business sale to Neurosterix Pharma Sàrl, which generated CHF 5.0 million in cash proceeds and a 20% equity stake in Neurosterix US holdings LLC valued at CHF 9.4 million.The company's cash position stood at CHF 3.8 million as of June 30, 2024. The H1 2024 results remain under review and may be subject to changes before final publication. A detailed financial report and corporate update will be presented on September 30, 2024, featuring CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev.
Addex Therapeutics announced a significant turnaround in its financial performance for H1 2024, posting a net profit of CHF 9.8 million compared to a net loss of CHF 5.1 million in H1 2023. This CHF 14.9 million improvement primarily stems from the April 2, 2024 partial business sale to Neurosterix Pharma Sàrl, which generated CHF 5.0 million in cash proceeds and a 20% equity stake in Neurosterix US holdings LLC valued at CHF 9.4 million.The company's cash position stood at CHF 3.8 million as of June 30, 2024. The H1 2024 results remain under review and may be subject to changes before final publication. A detailed financial report and corporate update will be presented on September 30, 2024, featuring CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev.
Addex Therapeutics宣布其2024年上半年的财务表现实现显著扭转,净利润为980万瑞士法郎,而2023年上半年为净亏损510万瑞士法郎。这1490万瑞士法郎的改善主要源于2024年4月2日与Neurosterix Pharma Sàrl的部分业务出售,该交易产生了500万瑞士法郎的现金收益,以及对Neurosterix US holdings LLC的20%股权,估值为940万瑞士法郎。截至2024年6月30日,公司现金状况为380万瑞士法郎。2024年上半年的业绩仍在审查中,最终公布前可能会有所更改。详细的财务报告和公司更新将于2024年9月30日公布,由首席执行官TIM Dyer和转化科学负责人Mikhail Kalinichev进行介绍。
Addex Therapeutics宣布其2024年上半年的财务表现实现显著扭转,净利润为980万瑞士法郎,而2023年上半年为净亏损510万瑞士法郎。这1490万瑞士法郎的改善主要源于2024年4月2日与Neurosterix Pharma Sàrl的部分业务出售,该交易产生了500万瑞士法郎的现金收益,以及对Neurosterix US holdings LLC的20%股权,估值为940万瑞士法郎。截至2024年6月30日,公司现金状况为380万瑞士法郎。2024年上半年的业绩仍在审查中,最终公布前可能会有所更改。详细的财务报告和公司更新将于2024年9月30日公布,由首席执行官TIM Dyer和转化科学负责人Mikhail Kalinichev进行介绍。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息